- Home
- PSO vs CORT Comparison
PSO vs CORT Comparison
Compare PSO & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSO | CORT |
|---|---|---|
| Founded | 1844 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 8.6B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | PSO | CORT |
|---|---|---|
| Price | $14.17 | $35.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $111.00 |
| AVG Volume (30 Days) | 659.6K | ★ 2.6M |
| Earning Date | 03-03-2026 | 02-25-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 31.65 | N/A |
| EPS | ★ 0.90 | 0.87 |
| Revenue | ★ $4,822,578,436.00 | $741,172,000.00 |
| Revenue This Year | $2.36 | $23.96 |
| Revenue Next Year | $5.20 | $43.40 |
| P/E Ratio | ★ $15.71 | $40.01 |
| Revenue Growth | N/A | ★ 17.92 |
| 52 Week Low | $12.85 | $32.99 |
| 52 Week High | $17.90 | $117.33 |
Technical Indicators
Market Signals| Indicator | PSO | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 59.48 | 18.09 |
| Support Level | $13.55 | $32.99 |
| Resistance Level | $14.23 | $85.34 |
| Average True Range (ATR) | 0.13 | 4.17 |
| MACD | -0.01 | -5.98 |
| Stochastic Oscillator | 91.85 | 5.45 |
Price Performance
Historical ComparisonAbout PSO Pearson Plc
UK-listed Pearson is a testing and educational provider. Pearson's primary operations are in assessment and qualification testing and higher education, but they also provide English education and testing, virtual learning, prehiring testing and screening, and upskilling/reskilling. The company divested noncore businesses, including the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.